Sanctuary Advisors LLC Reduces Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Sanctuary Advisors LLC trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,486 shares of the biopharmaceutical company’s stock after selling 2,553 shares during the quarter. Sanctuary Advisors LLC’s holdings in Halozyme Therapeutics were worth $1,649,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in HALO. Private Advisor Group LLC raised its holdings in shares of Halozyme Therapeutics by 6.2% during the 3rd quarter. Private Advisor Group LLC now owns 24,163 shares of the biopharmaceutical company’s stock worth $1,383,000 after acquiring an additional 1,410 shares during the period. International Assets Investment Management LLC increased its position in Halozyme Therapeutics by 5,623.9% during the third quarter. International Assets Investment Management LLC now owns 36,576 shares of the biopharmaceutical company’s stock worth $20,940,000 after purchasing an additional 35,937 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Halozyme Therapeutics by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,582 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 782 shares during the period. State of Alaska Department of Revenue raised its stake in Halozyme Therapeutics by 7.2% during the third quarter. State of Alaska Department of Revenue now owns 14,838 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 995 shares during the period. Finally, Arbor Investment Advisors LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at about $1,027,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on HALO shares. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. HC Wainwright raised their price objective on Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Finally, Benchmark restated a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Stock Up 1.3 %

Shares of NASDAQ:HALO opened at $58.50 on Tuesday. The firm has a market capitalization of $7.20 billion, a PE ratio of 17.06, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm’s 50-day moving average is $53.67 and its two-hundred day moving average is $54.67.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.